INVESTIGATING THE PREVALENCE AND ASSOCIATION OF HELICOBACTER PYLORI cagA AND iceA GENES WITH GASTRITIS AND PEPTIC ULCER DISEASE
Main Article Content
Abstract
Background: The roles of cagA and iceA genes in the development of Helicobacter pylori (H. pylori)- induced gastritis and peptic ulcer disease remain unclear. Objectives: To determine the prevalence of H. pylori cagA and iceA genes and to investigate the association between these genes with gastritis and peptic ulcer disease. Materials and methods: A cross-sectional descriptive study was conducted on 69 patients with gastritis and peptic ulcer disease infected with H. pylori. The study was carried out at Can Tho Central General Hospital and Can Tho University of Medicine and Pharmacy Hospital from July 2025 to January 2026. The cagA and iceA genes were identified using PCR from gastric mucosa specimens. Results: The prevalence of cagA-positive and iceA-positive genes were 79,7% and 73,9% (37,7% iceA1 and 36,2% iceA2) respectively. Three genotypes of the iceA2 gene were identified: 24 aa, 59 aa, and 94 aa, with the 59 aa being the most common (72%). The presence of the iceA1 gene was significantly associated with peptic ulcers (Adjusted OR = 6,05; 95% CI: 1,40 - 26,18). Conclusions: The prevalence of H. pylori strains carrying cagA and iceA genes is high (79,7% and 73,9%, respectively). The iceA1 gene is associated with peptic ulcer disease.
Keywords
Helicobacter pylori, cagA, iceA, gastritis and peptic ulcer disease
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
References
2. Mohammed A., Atef S., Ahmed E., Erwa E., Thanaa A., et al. Helicobacter pylori vacA, cagA and iceA genotypes in dyspeptic patients from southwestern region, Saudi Arabia: distribution and association with clinical outcomes and histopathological changes. BMC gastroenterology. 2019. 19, 1-11, doi: 10.1186/s12876-019-0934-z.
3. Yakoob J., Abbas Z., Khan R., Salim S.A., Abrar A., et al. Helicobacter pylori: correlation of the virulence marker iceA allele with clinical outcome in a high prevalence area. British Journal of Biomedical Science. 2015. 72(2),67-73. DOI: 10.1080/09674845.2015.11666799.
4. Toyoshima O., Nishizawa T., Yoshida S., Matsuno T., Odawara N., et al. Consistency between the endoscopic Kyoto classification and pathological updated Sydney system for gastritis: A cross‐sectional study. Journal of Gastroenterology and Hepatology. 2022. 37 (2), 291-300. DOI: 10.1111/jgh.15693.
5. Mohammad Y., David A. Peptic ulcer diseases. In Yamada’s Textbook of Gastroenterology, 3 Volume 1, 7th Edition.: John Wiley & Sons Ltd; 2022. 924-38 p.
6. Nguyen Tung Lam, Uchida T., Tsukamoto Y., Trinh D.T., Long T., et al. Helicobacter pylori infection and gastroduodenal diseases in Vietnam: a cross-sectional, hospital-based study. BMC gastroenterology. 2010. 10, 1-7, doi: 10.1186/1471-230X-10-114.
7. El Khadir M., Alaoui B.S., Benajah D.A., Karima E.R., Sidi A.I., et al. VacA and CagA status as biomarker of two opposite end outcomes of Helicobacter pylori infection (gastric cancer and duodenal ulcer) in a Moroccan population. PloS One. 2017. 12 (1), 1-14, doi: 10.1371/journal.pone.0170616.
8. Phan Trung Nam, Santona A., Tran V.H., Tran T.N.H., Le V.A., et al. Genotyping of Helicobacter pylori shows high diversity of strains circulating in central Vietnam. Infection, Genetics and Evolution. 2017. 52, 19-25, doi: 10.1016/j.meegid.2017.04.014.
9. Namikawa K., Purisevic F.L., Thorsteinsson J.B., Bjornsson E.S. Helicobacter pylori Across Continents: Contrasts in Epidemiology, Genetics, Clinical Impact, and Management Between East and West. Int J Mol Sci. 2025. 26 (23), doi: 10.3390/ijms262311408.
10. Võ Phúc Đại, Nguyễn Thanh Liêm, Hà Tấn Đức. Tỷ lệ mang gen cagA của vi khuẩn Helicobacter pylori và mối liên quan với bệnh lý viêm và loét dạ dày - tá tràng. Tạp chí Y Học Việt Nam. 2025. 556 (1), 255-9, doi: 10.51298/vmj.v551i1.14521.
11. Huang X., Deng Z., Zhang Q., Li W., Wang B., Li M. Relationship between the iceA gene of Helicobacter pylori and clinical outcomes. Therapeutics and Clinical Risk Management. 2016. 12, 1085-92, doi: 10.2147/TCRM.S107991.